A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
- Conditions
- Vitiligo
- Registration Number
- JPRN-jRCT2031230659
- Lead Sponsor
- Kawai Norisuke
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 400
Participants >=18 years of age at Screening in Study B7981040. Adolescents (12 to <18 years of age at Screening in the parent study) are also eligible for this study if approved by the local IRB/EC and regulatory health authority.
Participants who met the eligibility criteria and completed 52 weeks of study intervention for stable or active nonsegmental vitiligo in Study B7981040
The BL visit/first dose in Study B7981041 must be within 30 days after the week 52 visit in Study B7981040
Participant met the parent study (Study 7981040) discontinuation criteria or discontinued the parent study for any safety-related event
Any active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method